Feasibility of nitric oxide administration by neonatal helmet-CPAP: a bench study

Paediatr Anaesth. 2007 Sep;17(9):851-5. doi: 10.1111/j.1460-9592.2007.02297.x.

Abstract

Background: Inhaled nitric oxide (NO) may have a role in the treatment of preterm infants with respiratory failure. We evaluated the feasibility of administering NO therapy by a new continuous positive airway pressure (CPAP) system (neonatal helmet-CPAP).

Methods: While maintaining a constant total flow of 8, 10, and 12 l.min(-1), NO concentrations were progressively increased to 5, 10, 20, and 40 p.p.m. in the neonatal helmet-CPAP pressure chamber (5 cmH2O). NO, NO2, and O2 concentrations were measured in the pressure chamber and the immediate external environment.

Results: In the chamber, NO2 levels remained low (<or=0.8 p.p.m.) at inhaled therapeutic NO concentrations (5, 10, 20, and 40 p.p.m.). The lower O2 concentrations were 95% at 40 p.p.m. NO levels. Leakage of NO and NO2 to the surrounding environment was negligible.

Conclusions: NO administration is safe and feasible using the neonatal helmet-CPAP system. This method allows the delivery of accurate NO levels and high O2 concentrations avoiding NO2 accumulation. Further experimental and clinical studies are needed.

MeSH terms

  • Administration, Inhalation
  • Bronchodilator Agents / administration & dosage*
  • Bronchodilator Agents / therapeutic use*
  • Continuous Positive Airway Pressure*
  • Feasibility Studies
  • Humans
  • Infant, Newborn
  • Nitric Oxide / administration & dosage*
  • Nitric Oxide / analysis
  • Nitric Oxide / therapeutic use*
  • Oxygen / analysis
  • Oxygen Inhalation Therapy / instrumentation
  • Oxygen Inhalation Therapy / methods
  • Respiratory Distress Syndrome, Newborn / drug therapy*
  • Respiratory Distress Syndrome, Newborn / physiopathology
  • Temperature

Substances

  • Bronchodilator Agents
  • Nitric Oxide
  • Oxygen